Skip to main content
SpringerLink
Log in

Opinion and Evidence in Hypertension and Cardiovascular Disease Prevention

  • From the World Literature
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarising information selected from over 1600 biomedical journals, this newsletter is produced by Adis International Limited and is available in a variety of formats. Please contact your nearest Adis office for subscription details. The use of trade names, identified by ['~'] or the use of a registered (®) or trade mark (™), is for product identification purposes only and does not imply endorsement.

  2. Study on Cognition and Prognosis in the Elderly.

  3. The study was supported by AstraZeneca.

  4. This trial was sponsored by Pfizer.

  5. This study received financial support from Roche Pharma, France.

  6. CAndesaRtan combined with DIuretic in hypertensiOn

  7. This study was supported by a grant from Takeda Italia Farmaceutici.

  8. The study was funded by an unrestricted grant from Bristol-Myers Squibb.

  9. Costs were considered from the perspective of the UK National Health Service (NHS), and included those related to the study drugs, concomitant antihypertensives (permitted in patients not achieving target blood pressure of ≤135/85mm Hg) and management of ESRD (including dialysis and transplantation). Costs were discounted at a rate of 6% per annum and benefits at 1.5% per annum.

  10. This study was funded by GlaxoSmithKline.

References

  1. Meredith PA, Reid JL. Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients: a retrospective analysis of a general practice study. Am J Cardiovasc Drugs 2004; 4(3): 195–200

    Article  PubMed  CAS  Google Scholar 

  2. Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). SCOPE Study Group. J Am Coll Cardiol 2004; 44`(6): 1175–80

    Google Scholar 

  3. White WB, Lacourciere Y, Gana T, et al. Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. Am Heart J 2004; 148(4): 628–34

    Article  PubMed  CAS  Google Scholar 

  4. Galderisi M, Cicala S, D’Errico A, et al. Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease. J Hypertens 2004; 22(11): 2201–8

    Article  PubMed  CAS  Google Scholar 

  5. Yosefy C, Magen E, Kiselevich A, et al. Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004; 44(2): 215–22

    Article  PubMed  CAS  Google Scholar 

  6. De Luca N, Mallion J-M, O’Rourke MF, et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON Echocardiography Study. REASON Project. Am J Hypertens 2004; 17(8): 660–7

    PubMed  Google Scholar 

  7. Wright Jr JT, Sica DA, Gana TJ, et al. Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans. Am J Hypertens 2004; 17(9): 734–42

    Article  PubMed  CAS  Google Scholar 

  8. Flynn JT, Newburger JW, Daniels SR, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension: PATH-I Investigators. J Pediatr 2004; 145(3): 353–9

    Article  PubMed  CAS  Google Scholar 

  9. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110(24): 3687–92

    Article  PubMed  CAS  Google Scholar 

  10. Guy-Grand B, Drouin P, Eschwege E, et al. Effects of orlistat on obesity-related diseases: a six-month randomized trial. Diabetes Obes Metab 2004; 6(5): 375–83

    Article  PubMed  CAS  Google Scholar 

  11. Mancia G, Omboni S, CARDIO (CAandesaRtan combined with DIuretic in hypertensiOn) Study Group. Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients. Blood Press 2004; 13Suppl. 2: 11–7

    Article  Google Scholar 

  12. Moriwaki H, Uno H, Nagakane Y, et al. Losartan, an angiotensin II (AT(1)) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke. J Hum Hypertens 2004; 18(10): 693–9

    Article  PubMed  CAS  Google Scholar 

  13. Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004; 18(10): 733–8

    Article  PubMed  CAS  Google Scholar 

  14. Ellis D, Moritz ML, Vats A, et al. Antihypertensive and renoprotective efficacy and safety of losartan: a long-term study in children with renal disorders. Am J Hypertens 2004; 17(10): 928–35

    PubMed  CAS  Google Scholar 

  15. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364(9446): 1684–9

    Article  PubMed  CAS  Google Scholar 

  16. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. GEMINI Investigators. JAMA 2004; 292(18): 2227–36

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opinion and Evidence in Hypertension and Cardiovascular Disease Prevention. High Blood Press Cardiovasc Prev 12, 45–51 (2005). https://doi.org/10.2165/00151642-200512010-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151642-200512010-00007

Search

Navigation